Current framework of biotechnology products according to the available pharmacoeconomic studies;Marco actual de los productos biotecnológicos según los estudios farmacoeconómicos disponibles

Medicina Clinica

Volumn 120, Issue 13, 2003, Pages 498-504

  Clemente Bautista, Susana ^a   Mendante Barrenechea, Luís ^a   Montoro Ronsano, José Bruno ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Biotechnology; Quality adjusted life years; Years of life saved

Indexed keywords

ABCIXIMAB; ALGLUCERASE; ALPHA INTERFERON; ALTEPLASE; BASILIXIMAB; BECAPLERMIN; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; DACLIZUMAB; ERYTHROPOIETIN; HEPATITIS B VACCINE; HYDROXYUREA; IMIGLUCERASE; INFLIXIMAB; INTERFERON; INTERLEUKIN 11; LAMIVUDINE; LEPIRUDIN; OKT 3; PALIVIZUMAB; RECOMBINANT FOLLITROPIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RETEPLASE; RIBAVIRIN; RITUXIMAB; TRASTUZUMAB; UNINDEXED DRUG; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BIOTECHNOLOGY; CHILD; CHRONIC KIDNEY FAILURE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEBRILE NEUTROPENIA; GAUCHER DISEASE; HEART INFARCTION; HEPATITIS B; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; MELANOMA; METHODOLOGY; NONHODGKIN LYMPHOMA; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY TRACT INFECTION; STANDARD; VIRUS INFECTION;

EID: 0037986711     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13045807     Document Type: Article

References (44)

1. Herreros A, Cabañas MJ, Ferrari JM, Del Puy M. Fármacos obtenidos por biotecnología. En: SEFH, editores. Farmacia hospitalaria. Madrid: EMISA, 1992; p. 1681-709.
2. Tami J, Evens RP. Evaluation of biotechnology products. Pharmacotherapy 1996;16:527-36.
3. Piascik P. 1996 survey of biotechnology drugs. J Am Pharm Assoc 1996; 36:545-6.
4. Bush P. Overview of biotechnology. J Pharma Practice 1998;11:6-12.
5. Piascik P. Pharmaceutical care of biotechnology: distribution, pharmacoeconomics, product evaluation and specialty practice considerations. J Pharm Practice 1998;9:38-45.
6. Santell JP. Projecting future drug expenditures - 1994. Am J Hosp Pharm 1994;51:177-87.
7. Tami J, Evens RP. Evaluation of biotechnology products. Pharmacotherapy 1996;16:527-36.
8. DiPiro JT. Biotechnology: are you ready to meet the challenge? Aust J Hosp Pharm 1996;26:74-8.
9. Soto J. Medicina basada en la evidencia: pero ¿en qué evidencia? Med Clin (Barc) 1998;111:539-41.
10. Anónimo. ASCO and ACOG update: breast cancer in prevention. Oncology Issues 1999;14:1327-3.
11. Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, Goldman L. Long term cost-effectiveness of various initial monotherapies for mild to moderate hipertension. JAMA 1990;263:407-13.
12. Elliot WJ, Weir DR. Comparative cost-efectiveness of HMGcoA reductasa inhibitors in secondary prevention of acute myocardial infarction. Am J Health Sys 1999,56:1726-32.
13. Gillis JC, Goa KL. Streptokinase. A pharmacoeconomic appraisal of its use in the management of acute myocardial infarction. Pharmacoeconomics 1996;10:284.
14. Raftery J. NICE: faster acces to modern treatments? Analysis of guidance on health technologies. BMJ 2001;323:1300-3.
15. Louis-Jacques O, Olson AD. Cost-benefit analysis of interferon therapy in children with chronic active hepatitis B. J Pediatric Gastroenterol Nutr 1997;24:25-32.
16. Shiell A, Brown S, Farrell GC. Hepatitis C: an economic evaluation of extended treatment with interferon. Med J Aust 1999;171:189-93.
17. Sinha M, Das A. Cost efectiveness analysis of different strategies of management of chronic hepatitis C infection in children. Pediatr Infect Dis J 2000;19:23-30.
18. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995;22:1863-73.
19. Bennet WG, Pauker SG, Davis GL, Wong JB. Modeling therapeutic benefit in the midst of uncertainty. Therapy for hepatitis C. Dig Dis Sci 1996; 41:56S-61S.
20. Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000;17:409-27.
21. Messori A, Becagli P, Trippoli S, Tendi E. A retrospective cost-efectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur J Cancer 1997;33 :1373-9.
22. Wirt DP, Giles FJ, Oken MM, Solal-Celigny P, Beck JR. Cost-effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma. Leuk Lymphoma 2001;40:565-79.
23. Hillegass WB, Newman AR, Raco DL. Economic issues in glycoprotein IIb/IIIa receptor therapy. Am Heart J 1999;138(Suppl):24-32.
24. Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999;354:2019-24.
25. Hillegass WB, Newman AR, Raco DL. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications. Pharmacoeconomics 2001;19:41-55.
26. Wiebe T, Fergusson P, Horne D, Shanahan M, MacDonald A, Heise L, et al. Hepatitis B immunization in a low-incidence province of Canada: comparing alternative strategies. Med Decis Making 1997;17:472-82.
27. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-efectiveness analysis. Ann Intern Med 1993;118:298-306.
28. Deuson RR, Brodovicz KG, Barker I, Zhou F, Euler GL. Economic analysis of a child vaccination project among Asian Americans in Philadelphia. Arch Pediatric Adolesc Med 2001;155:909-14.
29. Miller MA, McCann. Policy analysis of the use of hepatitis B, Haemophilus influenzae type B-Streptococcus pneumoine- conjugate and rotavirus vaccines in national immunization schedules. Health Econ 2000;9: 19-35.
30. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Amstrong PW, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24.
31. Ramanathan K, Ellis CJ, White HD. Thrombolytic therapy in the elderly. Pharmacoeconomic considerations. Drugs Aging 1996;8:237-44.
32. Pelc A, Dardenne J, Frelon JH, Hanania G. Incremental cost-effectiveness ratio of alteplase in patients with acute myocardial infarction in the Frenach setting. Pharmacoeconomics 1997;11:595-60.
33. Shiell A, Briggs A, Farrell GC. The cost efectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust 1994;160:268-72.
34. Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Cost-efectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 2000;33:651-8.
35. Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 1996;125:541-8.
36. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-efectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrcs 1999;104:419-27.
37. Silber JH, Fridman M, Shpilsky A, Even-Shoshan O, Smink DS, Jayaraman J, et al. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breat cancer. J Clin Oncol 1998;16: 2435-44.
38. Bobey N, Woodman RC. Neutropenic complications in advanced-stage non-Hoddgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF). Clin Inv Med 1998;21:63-70.
39. Whittington R, Goa KL. Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease. Pharmacoeconomics 1995;7:63-90.
40. Leese B, Hutton J, Maynard A. A comparison of the costs and benefits of recombinant human erythropoetin (epoetin) in the treatment of chronic renal failure in 5 European countries. Pharmacoeconomics 1992;1:346-56.
41. Soto J. Utilidad de la incorporación de análisis de evaluación económica en los protocolos de los ensayos clínicos. Med Clin (Barc) 1998;110: 157-8.
42. Antoñanzas F. Evaluación económica aplicada a los medicamentos: características y metodología. En: Sacristán JA, Badía X, Rovira J, editores. Farmacoeconomía: evaluación económica de medicamentos. Madrid: Editores Médicos, 1995; p. 31-50.
43. Martínez MJ. Impacto económico del uso de anticuerpos monoclonales. Seminario «Nuevos anticuerpos monoclonales». Actas del XLV Congreso Nacional de Farmacia Hospitalaria. Las Palmas de Gran Canaria, octubre 2000.
44. Puigventos F. Novedades terapéuticas año 2000: Los retos del clínico, los retos del gestor. Med Clin (Barc) 2001;116:465-8.